spacer
home > ebr > summer 2017 > strategic advantage
PUBLICATIONS
European Biopharmaceutical Review

Strategic Advantage

Pharmacovigilance (PV) is beginning to touch more aspects of life sciences organisations in the form of additional functions as well as international operations, including affiliates. Overcoming silos and establishing closer collaboration between PV and quality operations is a growing priority and, as circumstances evolve, responsibility for the monitoring of safety and associated systems will have to be shared by an increasingly diverse range of stakeholders.

Quality Rules


One thing the life sciences industry cannot escape is a heightened emphasis on quality as inspections increase. Although this presents certain obstacles, it also prompts companies to put better systems and processes in place senior management now understands the importance of PV and are beginning to allocate more resources to it.

The conceivable downside is that too much attention on compliance could detract from the real motivation underlying all of this which is, of course, to improve patient safety and public confidence. Two ways of keeping things in clear focus are to get teams working together more readily and to take shared responsibility for making improvements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Cheryl Key, MBBS, MFPM, is Head of Practice PV Platform Services and Principal Medic at ProductLife Group, with final responsibility for all projects, programmes and engagements in the platform, as well as for day-to-day management of the platform team. She has a medical degree from Charing Cross and Westminster Medical School, UK, a diploma in pharmaceutical medicine, membership of the Royal College of General Practitioners and membership of the Faculty of Pharmaceutical Medicine. Cheryl is also on the Specialist Register at the General Medical Council for Pharmaceutical Medicine and a member of the board of the Faculty of Pharmaceutical Medicine.
spacer
Cheryl Key
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Saneca to drive R&D Initiative following 1.5 million funding


More info >>

White Papers

Orthogonal Approaches for the Analysis of Protein Sequence

Ludger Ltd

One of the most important classes of biopharmaceuticals is monoclonal antibodies. They are expressed from living cells, and are consequently subject to complex biochemical pathways. Not all of these routes are fully understood, and many are sensitive to the subtlest of environmental changes. Changes such as these can affect the final biopharmaceutical sequence, structure and post-translational modifications, not to mention any changes that may occur during further purification. This often means that the final product from one batch may be different from the last in another batch. Each batch is a complicated mix of similar molecules, and analysis of the degree of batch-to-batch variation is therefore very important to the establishment of the drug's safety for medicinal use and patient administration.
More info >>

 
Industry Events

CPhI Worldwide 2017

24-26 October 2017, Messe Frankfurt, Germany

CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, hosts more than 42,000 visiting pharma professionals over three days. 2,500+ exhibitors from 153 countries gather at the event to network and take advantage of more than 150 free industry seminars. The exhibition covers every sector of the pharmaceutical market under one roof.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement